ProCE Banner Activity

Breast Cancer: Testing and Treatment ESR1 Mutations in Recurrent HR+ HER2-

Video

Paolo Tarantino, MD reviews the emerging role of ESR1 mutation testing in patients with recurrent HR+ HER2- breast cancer. This presentation discusses guidelines and recommendations for ESR1 testing along with recent data releases from ESMO and SABCS for therapies in patients harboring ESR1 mutations.

 

Released: April 03, 2024

Expiration: July 30, 2024

Faculty

Paolo Tarantino

Paolo Tarantino, MD

Advanced Research Fellow
Harvard Medical School
Department of Breast Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts